Evening primrose oil (EPO) is extracted from the seeds of Oenothera biennis, a wildflower native to North America. It is one of the richest plant-based sources of gamma-linolenic acid (GLA), a conditionally essential omega-6 fatty acid that most people cannot synthesize efficiently from dietary linoleic acid alone. The oil has been used medicinally since the 1970s, initially for eczema and inflammatory conditions, and its clinical applications have expanded to include women's hormonal health.

GLA from EPO is converted in the body to dihomo-gamma-linolenic acid (DGLA), which serves as the precursor to prostaglandin E1 (PGE1) — an eicosanoid with anti-inflammatory, vasodilatory, and platelet-inhibitory properties. Increased PGE1 activity may reduce the hormone-driven inflammation underlying PMS symptoms, breast tenderness, and skin barrier dysfunction. In women with mastalgia and PMS, research suggests that deficient GLA-to-DGLA conversion — possibly due to reduced delta-6-desaturase enzyme activity — contributes to symptoms, and supplemental GLA bypasses this enzymatic bottleneck.

Oral softgel capsules are the most clinically studied delivery form. Liquid oil is available for those who prefer to add it to food, though it is prone to oxidation and must be stored refrigerated and away from light. Topical formulations are used for skin conditions such as eczema and dry skin, but the evidence base for topical EPO is weaker than for oral supplementation. Some products combine EPO with borage oil (a higher-GLA source) to reduce the number of capsules needed.

• Premenstrual syndrome (PMS)
• Cyclic mastalgia (breast pain)
• Atopic eczema / dry skin
• Menopausal symptoms
• Rheumatoid arthritis

• Recurrence of cyclic mastalgia (ongoing supplementation may prevent symptom return between menstrual cycles based on the mastalgia RCT literature)

• Borage seed oil — Contains approximately 20–26% GLA — significantly higher than EPO — making it the most concentrated natural food-based GLA source, though it is typically used as a supplement oil rather than a culinary staple.
• Black currant seed oil — Contains approximately 15–20% GLA along with alpha-linolenic acid, providing a balanced omega fatty acid profile with meaningful GLA content comparable to high-quality EPO.
• Hemp seeds and hemp seed oil — Contains GLA at lower concentrations (1–4%) but is widely available and provides a favorable omega-3 to omega-6 ratio alongside GLA, supporting anti-inflammatory pathways.
• Spirulina — One of the few non-oil food sources containing meaningful GLA (approximately 1% of dry weight), making it a useful dietary contributor for those seeking GLA from whole foods.
• Oats — Contain trace amounts of GLA and support delta-6-desaturase enzyme activity (which converts linoleic acid to GLA endogenously) through their zinc and magnesium content, indirectly supporting GLA status.

• Nausea and mild gastrointestinal upset (most common, particularly at higher doses)
• Loose stools or diarrhea
• Headache (reported in some trials)
• Bloating
• Theoretical increased bleeding risk (clinically significant mainly with concurrent anticoagulant use)
• Rare: lowered seizure threshold (primarily a concern with phenothiazine co-administration)

• Recommended daily: Typical clinical doses range from 3,000–6,000 mg/day of EPO (providing approximately 240–480 mg GLA at 8% GLA content), taken in divided doses. For mastalgia and PMS, most trials used 3,000–4,000 mg/day. For RA, trials have used up to 6,000 mg/day. Check label GLA content rather than relying solely on total mg.
• Best time of day: Divide doses across meals (e.g., morning and evening with food). No strong evidence favoring a specific time of day.
• With or without food: Always take with food — fat-containing meals enhance GLA absorption and reduce gastrointestinal side effects.
• Time to effect: Minimum 4–6 weeks for initial effects; 8–12 weeks for full benefit assessment. Fatty acid membrane incorporation takes time.
• How long to take it: Most clinical trials have run for 3–12 months of continuous use. For cyclic conditions (PMS, mastalgia), some practitioners recommend taking EPO continuously rather than only in the luteal phase, as fatty acid repletion requires sustained supplementation. Long-term safety beyond 12 months is not well characterized in RCTs; periodic reassessment is reasonable.